Product Code: HIT 10630
The global AI in protein engineering market is projected to reach USD 3.82 billion by 2031 from USD 1.44 billion in 2026, at a CAGR of 21.6% from 2026 to 2031. Growth in the AI in protein engineering market is driven by rising pharmaceutical R&D expenditure, increasing drug development costs, and the need to improve the productivity of protein discovery and design.
| Scope of the Report |
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Offering, AI Tool, Application, Protein Type, Protein Engineering Process, End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
The 25 selected drugmakers analyzed by IntuitionLabs reported approximately USD 185 billion in combined R&D spending in 2025, with Merck & Co. spending USD 15.8 billion, Johnson & Johnson USD 14.7 billion, and Eli Lilly USD 13.3 billion. Improving returns from these investments is especially important, as the average R&D cost per approved drug asset rose from USD 2.23 billion in 2024 to USD 2.67 billion in 2025. AI is increasingly viewed as a lever to address these costs and improve the efficiency of drug discovery and development. However, adoption remains constrained by implementation complexity and uncertain ROI; 71% of life sciences executives reported AI deployment progress, but only 45% reported measurable performance gains, while 61% identified external partnerships as important for accessing AI capabilities.
"In 2025, antibodies held the largest share of the market, by protein type"
By protein type, antibodies represented the largest share of the AI in protein engineering market in 2025. This leadership stems from the growing development of antibody-based therapeutics and the increasing need to improve the efficiency of antibody discovery and optimization. Pharmaceutical and biotechnology companies extensively utilize AI-powered protein engineering tools for antibody sequence generation, affinity optimization, specificity prediction, developability assessment, and stability optimization. The rising focus on innovative antibody modalities, including bispecific antibodies, antibody-drug conjugates, and other next-generation biologics, has further increased demand for AI-enabled antibody engineering. Moreover, generative AI and protein language models can explore large sequence spaces, prioritize promising candidates, and reduce experimental iterations, encouraging greater adoption of AI-based antibody engineering platforms.
"Protein optimization to register highest CAGR in the market, by process"
By process, protein optimization is expected to be the fastest-growing segment in the AI in protein engineering market, driven by the need to improve protein activity, stability, specificity, affinity, and developability while reducing experimental iterations. AI-enabled optimization is demonstrating measurable improvements; an AI-guided closed-loop platform achieved a 57-fold increase in enzyme activity within five engineering cycles and up to 104-fold improvement for another enzyme. AI-based computational filtering has also improved experimental success rates by 50-150%, enabling faster prioritization of high-performing protein variants. These advances are expected to accelerate adoption of protein language models, generative AI, and machine-learning-based optimization across pharmaceutical, biotechnology, and industrial protein-engineering workflows.
"Asia Pacific to witness the highest growth rate during the forecast period"
The Asia Pacific region is projected to register the highest growth rate in the AI in protein engineering market during the forecast period, supported by the rapid development of AI-enabled protein design capabilities, expanding computational biology infrastructure, and increasing integration of AI with high-throughput experimentation. In China, researchers at Shanghai Jiao Tong University developed the Venus-Pod protein dataset, which contains more than 9 billion protein sequences, including 2.43 billion antibody sequences and 500 million functionally annotated sequences, providing a strong foundation for AI-driven protein design and optimization. The region is also advancing AI-enabled experimental workflows; an automated platform developed in China can perform more than 100 protein expression, purification, and testing tasks within 24 hours, nearly 10 times as efficiently as manual workflows. In Japan, RevolKa raised JPY 210 million (approximately USD 1.4 million) in May 2025 to advance its AI-powered aiProtein technology and therapeutic programs. Furthermore, Singapore-based research at the National University of Singapore is integrating machine learning with ultra-high-throughput sorting and next-generation sequencing to generate large-scale sequence-function datasets for AI-driven protein engineering. These developments, alongside the growing ecosystem of AI-protein engineering startups, research institutes, and automated biofoundries, are expected to accelerate adoption of generative AI, protein language models, and machine learning across protein discovery, optimization, antibody engineering, and de novo protein design in APAC.
The breakdown of primary participants is as mentioned below:
- By Company Type - Tier 1: 34%, Tier 2: 46%, and Tier 3: 20%
- By Designation - C-level: 35%, Director-level: 25%, and Others: 40%
- By Region - North America: 30%, Europe: 45%, Asia Pacific: 20%, Middle East & Africa: 3%, Latin America: 2%
Key Players in the AI in Protein Engineering Market
The key players functioning in the AI in protein engineering market include Schrodinger, Inc. (US), XtalPi (China), Dassault Systemes (France), NVIDIA Corporation (US), Generate:Biomedicines (US), Absci Corp. (US), Insilico Medicine (US), Isomorphic Labs (UK), among others.
Research Coverage:
This research report categorizes the AI in protein engineering market by offering (software/platforms, services), by AI tool (machine learning & deep learning, protein language models, generative AI, structure-based AI, other tools), by application (next-generation biologics, molecular glues, data generation, antibody discovery and optimization, enzyme engineering, de novo protein design, protein stability and developability optimization, other applications), by protein type (antibodies, enzymes, cytokines & growth factors, peptides, fusion proteins, miniproteins, other proteins), by protein engineering process (protein discovery, protein design, protein optimization, protein characterization, experimental validation), by end user (pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations, industrial biotechnology companies, other end users), and by region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The report covers detailed information on major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in protein engineering market. A detailed analysis of key industry players provides insights into their business overview, solutions, and services; key strategies; and recent developments associated with the AI in protein engineering market. This report covers the competitive analysis of startups in the AI in protein engineering market ecosystem.
Reasons to Buy the Report
This report will help established firms and new entrants/smaller firms gauge the market's pulse, which, in turn, can help them gain a greater share of the market. Firms purchasing the report can use one or more of the strategies below to strengthen their market position.
This report provides insights on:
- Analysis of key drivers (increasing adoption of generative ai and protein foundation models, rising demand for next-generation biologics and engineered proteins, increasing availability of protein sequence, structure, and experimental datasets), restraints (limited availability of high-quality experimentally validated protein data, high cost and complexity of experimental validation), opportunities (expansion of AI-designed de novo proteins, growth of AI-enabled antibody discovery and optimization, increasing demand for proprietary protein-engineering datasets), and challenges (biosecurity and biosafety concerns, lack of standardized benchmarking across ai protein-engineering platforms) influencing the growth of the AI in protein engineering market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the AI in protein engineering market.
- Market Development: Comprehensive information on lucrative emerging markets, offerings, AI tools, applications, protein types, protein engineering processes, end users, and regions.
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in protein engineering market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in protein engineering market like Schrodinger, Inc. (US), XtalPi (China), Dassault Systemes (France), NVIDIA Corporation (US), Generate:Biomedicines (US), Absci Corp. (US), Insilico Medicine (US), Isomorphic Labs (UK), among others.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
- 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 LIMITATIONS
- 1.6 STAKEHOLDERS
2 EXECUTIVE SUMMARY
- 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
- 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
- 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
- 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 AI IN PROTEIN ENGINEERING MARKET OVERVIEW
- 3.2 AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION & COUNTRY
- 3.3 AI IN PROTEIN ENGINEERING MARKET: GEOGRAPHIC SNAPSHOT
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Increasing adoption of generative AI and protein foundation models
- 4.2.1.2 Rising demand for next-generation biologics and engineered proteins
- 4.2.1.3 Increasing availability of protein sequence, structure, and experimental datasets
- 4.2.2 RESTRAINTS
- 4.2.2.1 Limited availability of high-quality experimentally validated protein data
- 4.2.2.2 High cost and complexity of experimental validation
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Expansion of AI-designed de novo proteins
- 4.2.3.2 Growth of AI-enabled antibody discovery and optimization
- 4.2.3.3 Increasing demand for proprietary protein-engineering datasets
- 4.2.4 CHALLENGES
- 4.2.4.1 Biosecurity and biosafety concerns
- 4.2.4.2 Lack of standardized benchmarking across AI protein-engineering platforms
- 4.3 UNMET NEEDS AND WHITE SPACES
- 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
- 5.1 INDUSTRY TRENDS IN GLOBAL AI IN PROTEIN ENGINEERING MARKET
- 5.2 PORTER'S FIVE FORCES ANALYSIS
- 5.2.1 BARGAINING POWER OF SUPPLIERS
- 5.2.2 BARGAINING POWER OF BUYERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 THREAT OF NEW ENTRANTS
- 5.2.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.3 MACROECONOMIC INDICATORS
- 5.3.1 INTRODUCTION
- 5.3.2 GDP TRENDS AND FORECAST
- 5.3.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
- 5.4 VALUE CHAIN ANALYSIS
- 5.4.1 RESEARCH & PRODUCT DEVELOPMENT
- 5.4.2 DATA INPUTS & COMPUTATIONAL INFRASTRUCTURE
- 5.4.3 AI MODEL & PLATFORM DEVELOPMENT
- 5.4.4 PLATFORM DEPLOYMENT & INTEGRATION
- 5.4.5 MARKETING AND SALES
- 5.4.6 POST-SALE SERVICES
- 5.5 ECOSYSTEM ANALYSIS
- 5.6 PRICING ANALYSIS
- 5.6.1 INDICATIVE PRICE FOR AI IN PROTEIN ENGINEERING MARKET, BY OFFERING (2025)
- 5.6.2 INDICATIVE PRICE FOR AI IN PROTEIN ENGINEERING MARKET, BY REGION (2025)
- 5.7 KEY CONFERENCES AND EVENTS, 2026-2027
- 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.9 INVESTMENT AND FUNDING SCENARIO
- 5.10 CASE STUDY ANALYSIS
- 5.11 IMPACT OF 2025 US TARIFF - AI IN PROTEIN ENGINEERING MARKET
- 5.11.1 INTRODUCTION
- 5.11.2 KEY TARIFF RATES
- 5.11.3 PRICE IMPACT ANALYSIS
- 5.11.4 IMPACT ON COUNTRY/REGION
- 5.11.4.1 US
- 5.11.4.2 Europe
- 5.11.4.3 Asia Pacific
- 5.11.5 IMPACT ON END USERS
- 5.11.5.1 Pharmaceutical & biotechnology companies
- 5.11.5.2 Academic & research institutes
- 5.11.5.3 Contract research organizations
- 5.11.5.4 Industrial biotechnology companies
- 5.11.5.5 Other end users
6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTION
- 6.1 KEY EMERGING TECHNOLOGIES
- 6.1.1 GENERATIVE AI FOR PROTEIN DESIGN
- 6.1.2 PROTEIN LANGUAGE MODELS (PLMS)
- 6.1.3 STRUCTURE-BASED AI FOR PROTEIN ENGINEERING
- 6.2 COMPLEMENTARY TECHNOLOGIES
- 6.2.1 HIGH-PERFORMANCE COMPUTING (HPC) AND CLOUD COMPUTING
- 6.2.2 LABORATORY AUTOMATION AND HIGH-THROUGHPUT SCREENING
- 6.3 ADJACENT TECHNOLOGIES
- 6.3.1 COMPUTATIONAL CHEMISTRY AND MOLECULAR SIMULATION
- 6.3.2 BIOINFORMATICS AND BIOLOGICAL DATA ANALYTICS
- 6.4 TECHNOLOGY/PRODUCT ROADMAP
- 6.5 PATENT ANALYSIS
- 6.5.1 PATENT PUBLICATION TRENDS FOR AI IN PROTEIN ENGINEERING MARKET
- 6.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
- 6.6 FUTURE APPLICATIONS
- 6.6.1 AI-ENABLED INTELLIGENT PROTEIN DESIGN AND PREDICTION
- 6.6.2 AI-DRIVEN AUTOMATED PROTEIN ENGINEERING AND DESIGN-BUILD- TEST-LEARN
- 6.6.3 AI-ENABLED PERSONALIZED AND FUNCTION-SPECIFIC PROTEIN ENGINEERING
7 REGULATORY LANDSCAPE
- 7.1 REGIONAL REGULATIONS AND COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, & OTHER ORGANIZATIONS
- 7.1.2 REGULATORY FRAMEWORK
- 7.1.2.1 North America
- 7.1.2.2 Europe
- 7.1.2.3 ASIA PACIFIC
- 7.1.2.4 LATIN AMERICA
- 7.1.2.5 Middle East & Africa
- 7.1.3 INDUSTRY STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 8.1 INTRODUCTION
- 8.2 DECISION-MAKING PROCESS
- 8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
- 8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.3.2 BUYING CRITERIA
- 8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
- 8.5.1 UNMET NEEDS
- 8.5.2 END USER EXPECTATIONS
- 8.6 MARKET PROFITABILITY
9 AI IN PROTEIN ENGINEERING MARKET, BY OFFERING
- 9.1 INTRODUCTION
- 9.2 SOFTWARE/PLATFORMS
- 9.2.1 NICHE POINT SOLUTIONS
- 9.2.1.1 Specialized AI platforms expand protein engineering beyond end-to-end workflows
- 9.2.2 END-TO-END SOLUTIONS
- 9.2.2.1 Integrated AI platforms enable multi-stage protein engineering and accelerate candidate development
- 9.3 SERVICES
- 9.3.1 CONSULTING & ADVISORY SERVICES
- 9.3.1.1 Increasing complexity of AI adoption creates demand for protein engineering strategy and technical expertise
- 9.3.2 IMPLEMENTATION & INTEGRATION SERVICES
- 9.3.2.1 Integration complexity and data compatibility shape adoption of AI protein engineering solutions
- 9.3.3 TRAINING & SUPPORT SERVICES
- 9.3.3.1 Specialized skills gaps and evolving AI technologies sustain demand for training & support
10 AI IN PROTEIN ENGINEERING MARKET, BY AI TOOL
- 10.1 INTRODUCTION
- 10.2 MACHINE LEARNING & DEEP LEARNING
- 10.2.1 FOUNDATIONAL NEURAL ARCHITECTURES UNDERPIN MODERN PROTEIN ENGINEERING WORKFLOWS
- 10.3 PROTEIN LANGUAGE MODELS
- 10.3.1 EVOLUTION-SCALE SEQUENCE MODELS ENABLE PREDICTION AND GENERATION WITHOUT STRUCTURAL INPUTS
- 10.4 GENERATIVE AI
- 10.4.1 GENERATIVE MODELS MOVE ANTIBODY AND BINDER DESIGN FROM SCREENING TO PROGRAMMABLE DESIGN
- 10.5 STRUCTURE-BASED AI
- 10.5.1 ACCURATE COMPLEX PREDICTION SUPPORTS EPITOPE-SPECIFIC DESIGN AND AFFINITY ESTIMATION
- 10.6 OTHER TOOLS
- 10.6.1 ACTIVE LEARNING, BAYESIAN OPTIMIZATION, AND LAB-IN-THE-LOOP PLATFORMS COMPLEMENT CORE MODEL CLASSES
11 AI IN PROTEIN ENGINEERING MARKET, BY APPLICATION
- 11.1 INTRODUCTION
- 11.2 NEXT-GENERATION BIOLOGICS
- 11.2.1 THERAPEUTIC PROTEIN ENGINEERING
- 11.2.1.1 AI-optimized antibodies and engineered proteins move into late-stage development
- 11.2.2 MULTISPECIFIC & BISPECIFIC PROTEIN ENGINEERING
- 11.2.2.1 Dual-targeting formats attract record licensing investment as engineering platforms mature
- 11.2.3 CYTOKINE & GROWTH FACTOR ENGINEERING
- 11.2.3.1 Redesigned cytokines aim to separate therapeutic benefit from systemic toxicity
- 11.2.4 PROTEIN BINDER ENGINEERING
- 11.2.4.1 De novo binder design reaches double-digit to near-complete experimental hit rates
- 11.2.5 OTHER NEXT-GENERATION BIOLOGICS
- 11.2.5.1 Antibody-drug conjugates, scaffold fusions, and novel formats broaden engineering toolkits
- 11.3 MOLECULAR GLUES
- 11.4 DATA GENERATION
- 11.5 ANTIBODY DISCOVERY & OPTIMIZATION
- 11.5.1 ANTIBODY DISCOVERY
- 11.5.1.1 Generative design reduces dependence on immunization and library screening
- 11.5.2 ANTIBODY AFFINITY OPTIMIZATION
- 11.5.2.1 Computational lead optimization improves potency and dosing convenience
- 11.5.3 ANTIBODY SPECIFICITY & CROSS-REACTIVITY OPTIMIZATION
- 11.5.3.1 Atomic-level design enables selective binding and controlled species cross-reactivity
- 11.5.4 ANTIBODY DEVELOPABILITY OPTIMIZATION
- 11.5.4.1 Early developability screening reduces late-stage attrition risk
- 11.5.5 BISPECIFIC & MULTISPECIFIC ANTIBODY ENGINEERING
- 11.5.5.1 Maturing formats and design platforms extend beyond oncology T-Cell engagers
- 11.5.6 OTHER ANTIBODY ENGINEERING
- 11.5.6.1 Fc modification, half-life extension, and delivery formats broaden antibody differentiation
- 11.6 ENZYME ENGINEERING
- 11.7 DE NOVO PROTEIN DESIGN
- 11.8 PROTEIN STABILITY & DEVELOPABILITY OPTIMIZATION
- 11.9 OTHER APPLICATIONS
12 AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE
- 12.1 INTRODUCTION
- 12.2 ANTIBODIES
- 12.2.1 AI-DRIVEN ANTIBODY DESIGN AND OPTIMIZATION ACCELERATE NEXT-GENERATION BIOLOGICS DEVELOPMENT
- 12.3 ENZYMES
- 12.3.1 AI-POWERED ENZYME ENGINEERING EXPANDS APPLICATIONS ACROSS INDUSTRIAL BIOCATALYSIS
- 12.4 CYTOKINES & GROWTH FACTORS
- 12.4.1 ADVANCING PRECISION ENGINEERING OF CYTOKINES AND GROWTH FACTORS
- 12.5 PEPTIDES
- 12.5.1 AI ADDRESSES COMPLEXITY IN PEPTIDE SEQUENCE DESIGN AND FUNCTIONAL OPTIMIZATION
- 12.6 FUSION PROTEINS
- 12.6.1 AI IMPROVES MULTI-DOMAIN DESIGN OF FUSION PROTEINS
- 12.7 MINIPROTEIN
- 12.7.1 DE NOVO MINIPROTEIN DESIGN OPENS NEW OPPORTUNITIES FOR PRECISION BIOLOGICS
- 12.8 OTHER PROTEINS
- 12.8.1 EMERGING PROTEIN MODALITIES CREATE NEW OPPORTUNITIES FOR AI-ENABLED ENGINEERING
13 AI IN PROTEIN ENGINEERING MARKET, BY PROTEIN ENGINEERING PROCESS
- 13.1 INTRODUCTION
- 13.2 PROTEIN DISCOVERY
- 13.2.1 EXPANDING SEQUENCE AND STRUCTURE DATABASES ACCELERATE TARGET AND STARTING-POINT IDENTIFICATION
- 13.3 PROTEIN DESIGN
- 13.3.1 OPEN GENERATIVE MODELS MOVE DE NOVO DESIGN FROM PROOF OF CONCEPT TO BROAD EXPERIMENTAL VALIDATION
- 13.4 PROTEIN OPTIMIZATION
- 13.4.1 MACHINE LEARNING-GUIDED OPTIMIZATION IMPROVES AFFINITY, STABILITY, AND MANUFACTURABILITY ACROSS ITERATIVE CYCLES
- 13.5 PROTEIN CHARACTERIZATION
- 13.5.1 HIGHER-RESOLUTION STRUCTURAL AND BIOPHYSICAL ANALYSIS ANCHORS COMPUTATIONAL PREDICTIONS IN EXPERIMENTAL REALITY
- 13.6 EXPERIMENTAL VALIDATION
- 13.6.1 CLOUD LABS, PUBLIC COMPETITIONS, AND LAB-IN-THE-LOOP PLATFORMS SCALE WET-LAB TESTING
14 AI IN PROTEIN ENGINEERING MARKET, BY END USER
- 14.1 INTRODUCTION
- 14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 14.2.1 HIGH R&D INVESTMENTS AND GROWING AI INTEGRATION ACCELERATE PROTEIN ENGINEERING ADOPTION
- 14.3 ACADEMIC & RESEARCH INSTITUTES
- 14.3.1 ADVANCING PROTEIN SCIENCE THROUGH AI-ENABLED RESEARCH AND COMPUTATIONAL DESIGN
- 14.4 CONTRACT RESEARCH ORGANIZATIONS
- 14.4.1 AI HELPS CROS DIFFERENTIATE PROTEIN ENGINEERING SERVICES AND EXPAND OUTSOURCED DISCOVERY CAPABILITIES
- 14.5 INDUSTRIAL BIOTECHNOLOGY COMPANIES
- 14.5.1 AI-DRIVEN BIOCATALYST DEVELOPMENT ACCELERATES ADOPTION IN INDUSTRIAL BIOTECHNOLOGY
- 14.6 OTHER END USERS
- 14.6.1 EXPANSION OF AI-ENABLED PROTEIN ENGINEERING ACROSS DIVERSE APPLICATIONS TO BOOST SEGMENT
15 AI IN PROTEIN ENGINEERING MARKET, BY REGION
- 15.1 INTRODUCTION
- 15.2 NORTH AMERICA
- 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 15.2.2 US
- 15.2.2.1 AI-driven protein design and strong biopharmaceutical R&D support market growth
- 15.2.3 CANADA
- 15.2.3.1 Government support for AI innovation and biomanufacturing strengthens market growth
- 15.3 EUROPE
- 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 15.3.2 GERMANY
- 15.3.2.1 Strong pharmaceutical research base and AI innovation drive protein engineering adoption
- 15.3.3 FRANCE
- 15.3.3.1 Biopharma innovation and research commercialization support market expansion
- 15.3.4 UK
- 15.3.4.1 Regulatory innovation and AI-driven drug discovery accelerate adoption
- 15.3.5 ITALY
- 15.3.5.1 Pharmaceutical manufacturing strength and research modernization create opportunities
- 15.3.6 SPAIN
- 15.3.6.1 Strong pharmaceutical R&D and biopharma ecosystem support market growth
- 15.3.7 REST OF EUROPE
- 15.4 ASIA PACIFIC
- 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 15.4.2 CHINA
- 15.4.2.1 AI-driven protein engineering and biologics innovation reshape pharmaceutical development
- 15.4.3 JAPAN
- 15.4.3.1 Demographic pressures and AI innovation drive protein engineering adoption
- 15.4.4 INDIA
- 15.4.4.1 Cost-efficient innovation and biotechnology expansion support growth
- 15.4.5 AUSTRALIA
- 15.4.5.1 Translational research ecosystem supports AI-enabled protein engineering
- 15.4.6 SOUTH KOREA
- 15.4.6.1 Biotechnology Expansion and AI investments support protein engineering adoption
- 15.4.7 REST OF ASIA PACIFIC
- 15.5 LATIN AMERICA
- 15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 15.5.2 BRAZIL
- 15.5.2.1 Leading regional pharmaceutical research activity supports market growth
- 15.5.3 MEXICO
- 15.5.3.1 Pharmaceutical manufacturing base and growing R&D activity support AI adoption
- 15.5.4 REST OF LATIN AMERICA
- 15.6 MIDDLE EAST & AFRICA
- 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 15.6.2 GCC COUNTRIES
- 15.6.2.1 Healthcare transformation and biotechnology investments support market growth
- 15.6.2.2 Saudi Arabia
- 15.6.2.2.1 Vision 2030 investments accelerate biotechnology and AI-enabled protein engineering
- 15.6.2.3 UAE
- 15.6.2.3.1 Healthcare innovation and biotechnology initiatives support market growth
- 15.6.2.4 Other GCC countries
- 15.6.3 SOUTH AFRICA
- 15.6.3.1 Expanding biotechnology and research capabilities support market growth
- 15.6.4 REST OF MIDDLE EAST & AFRICA
16 COMPETITIVE LANDSCAPE
- 16.1 OVERVIEW
- 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN PROTEIN ENGINEERING MARKET
- 16.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
- 16.4 MARKET SHARE ANALYSIS, 2025
- 16.5 BRAND COMPARISON
- 16.6 VALUATION & FINANCIAL METRICS
- 16.6.1 FINANCIAL METRICS
- 16.6.2 COMPANY VALUATION
- 16.7 COMPANY EVALUATION MATRIX, KEY PLAYERS (2025)
- 16.7.1 STARS
- 16.7.2 EMERGING LEADERS
- 16.7.3 PERVASIVE PLAYERS
- 16.7.4 PARTICIPANTS
- 16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
- 16.7.5.1 Company footprint
- 16.7.5.2 Region footprint
- 16.7.5.3 Offering footprint
- 16.7.5.4 Application footprint
- 16.7.5.5 AI tool footprint
- 16.7.5.6 End user footprint
- 16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 16.8.1 PROGRESSIVE COMPANIES
- 16.8.2 RESPONSIVE COMPANIES
- 16.8.3 DYNAMIC COMPANIES
- 16.8.4 STARTING BLOCKS
- 16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
- 16.8.5.1 Detailed list of key startups/SMEs
- 16.8.5.2 Competitive benchmarking of startups/SMEs
- 16.9 COMPETITIVE SCENARIO
- 16.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
- 16.9.2 DEALS
17 COMPANY PROFILES
- 17.1 KEY PLAYERS
- 17.1.1 SCHRODINGER, INC.
- 17.1.1.1 Business overview
- 17.1.1.2 Products offered
- 17.1.1.3 Recent developments
- 17.1.1.3.1 Product enhancements
- 17.1.1.3.2 Deals
- 17.1.1.4 MnM view
- 17.1.1.4.1 Key strengths
- 17.1.1.4.2 Strategic choices
- 17.1.1.4.3 Weaknesses and competitive threats
- 17.1.2 XTALPI
- 17.1.2.1 Business overview
- 17.1.2.2 Products offered
- 17.1.2.3 Recent developments
- 17.1.2.4 MnM view
- 17.1.2.4.1 Key strengths
- 17.1.2.4.2 Strategic choices
- 17.1.2.4.3 Weaknesses and competitive threats
- 17.1.3 DASSAULT SYSTEMES
- 17.1.3.1 Business overview
- 17.1.3.2 Products Offered
- 17.1.3.3 Recent developments
- 17.1.3.3.1 Product launches/enhancements
- 17.1.3.3.2 Deals
- 17.1.3.4 MnM view
- 17.1.3.4.1 Key strengths
- 17.1.3.4.2 Strategic choices
- 17.1.3.4.3 Weaknesses and competitive threats
- 17.1.4 NVIDIA CORPORATION
- 17.1.4.1 Business overview
- 17.1.4.2 Products/Solutions offered
- 17.1.4.3 Recent developments
- 17.1.4.3.1 Product launches/enhancements
- 17.1.4.3.2 Deals
- 17.1.4.4 MnM view
- 17.1.4.4.1 Key strengths
- 17.1.4.4.2 Strategic choices
- 17.1.4.4.3 Weaknesses and competitive threats
- 17.1.5 GENERATE:BIOMEDICINES
- 17.1.5.1 Business overview
- 17.1.5.2 Products offered
- 17.1.5.3 Recent developments
- 17.1.5.3.1 Product enhancements
- 17.1.5.3.2 Deals
- 17.1.5.4 MnM view
- 17.1.5.4.1 Key strengths
- 17.1.5.4.2 Strategic choices
- 17.1.5.4.3 Weaknesses and competitive threats
- 17.1.6 ABSCI CORP.
- 17.1.6.1 Business overview
- 17.1.6.2 Products Offered
- 17.1.6.3 Recent developments
- 17.1.6.4 MnM view
- 17.1.6.4.1 Key strengths
- 17.1.6.4.2 Strategic choices
- 17.1.6.4.3 Weaknesses and competitive threats
- 17.1.7 INSILICO MEDICINE
- 17.1.7.1 Business overview
- 17.1.7.2 Products/Solutions offered
- 17.1.7.3 Recent developments
- 17.1.7.3.1 Product launches/enhancements
- 17.1.7.3.2 Deals
- 17.1.7.4 MnM view
- 17.1.7.4.1 Key strengths
- 17.1.7.4.2 Strategic choices
- 17.1.7.4.3 Weaknesses and competitive threats
- 17.1.8 CRADLE
- 17.1.8.1 Business overview
- 17.1.8.2 Products offered
- 17.1.8.3 Recent developments
- 17.1.8.3.1 Deals
- 17.1.8.3.2 Other developments
- 17.1.9 A-ALPHA BIO, INC.
- 17.1.9.1 Business overview
- 17.1.9.2 Products offered
- 17.1.9.3 Recent developments
- 17.1.9.3.1 Product launches
- 17.1.9.3.2 Deals
- 17.1.9.3.3 Other developments
- 17.1.10 ISOMORPHIC LABS
- 17.1.10.1 Business overview
- 17.1.10.2 Products offered
- 17.1.10.3 Recent developments
- 17.1.10.3.1 Deals
- 17.1.10.3.2 Other developments
- 17.1.11 CHAI DISCOVERY
- 17.1.11.1 Business overview
- 17.1.11.2 Products offered
- 17.1.11.3 Recent developments
- 17.1.11.3.1 Product launches and approvals
- 17.1.11.3.2 Deals
- 17.1.11.3.3 Other developments
- 17.1.12 EVOLUTIONARYSCALE (BIOHUB)
- 17.1.12.1 Business overview
- 17.1.12.2 Products offered
- 17.1.12.3 Recent developments
- 17.1.12.3.1 Product launches and approvals
- 17.1.12.3.2 Deals
- 17.1.12.3.3 Other developments
- 17.1.13 PROFLUENT
- 17.1.13.1 Business overview
- 17.1.13.2 Products offered
- 17.1.13.3 Recent developments
- 17.1.13.3.1 Deals
- 17.1.13.3.2 Other developments
- 17.1.14 BIGHAT BIO
- 17.1.14.1 Business overview
- 17.1.14.2 Products offered
- 17.1.14.3 Recent developments
- 17.1.14.3.1 Product launches
- 17.1.14.3.2 Deals
- 17.1.15 LATENT LABS
- 17.1.15.1 Business overview
- 17.1.15.2 Products offered
- 17.1.15.3 Recent developments
- 17.1.15.3.1 Product launches
- 17.1.15.3.2 Deals
- 17.1.15.3.3 Other developments
- 17.1.16 BASECAMP RESEARCH
- 17.1.16.1 Business overview
- 17.1.16.2 Products offered
- 17.1.16.3 Recent developments
- 17.1.16.3.1 Product launches
- 17.1.16.3.2 Deals
- 17.1.16.3.3 Other developments
- 17.1.17 NABLA BIO, INC.
- 17.1.17.1 Business overview
- 17.1.17.2 Products offered
- 17.1.17.3 Recent developments
- 17.1.17.3.1 Deals
- 17.1.17.3.2 Other developments
- 17.1.18 EVOZYNE
- 17.1.18.1 Business overview
- 17.1.18.2 Products offered
- 17.1.18.3 Recent developments
- 17.1.18.3.1 Deals
- 17.1.18.3.2 Other developments
- 17.1.19 LABGENIUS LIMITED
- 17.1.19.1 Business overview
- 17.1.19.2 Products offered
- 17.1.19.3 Recent developments
- 17.1.19.3.1 Deals
- 17.1.19.3.2 Other developments
- 17.2 OTHER PLAYERS
- 17.2.1 ARZEDA CORPORATION
- 17.2.2 MENTEN AI
- 17.2.3 PROTEINQURE
- 17.2.4 OUTPACE BIO
- 17.2.5 AI PROTEINS
- 17.2.6 MONODBIO
- 17.2.7 BIOMATTER INC.
- 17.2.8 DIFFUSE BIO
18 RESEARCH METHODOLOGY
- 18.1 RESEARCH APPROACH
- 18.1.1 SECONDARY RESEARCH
- 18.1.1.1 Key data from secondary sources
- 18.1.2 PRIMARY RESEARCH
- 18.1.2.1 Primary sources
- 18.1.2.2 Key data from primary sources
- 18.1.2.3 Breakdown of primaries
- 18.1.2.4 Insights from primary experts
- 18.2 RESEARCH METHODOLOGY DESIGN
- 18.3 MARKET SIZE ESTIMATION
- 18.4 MARKET BREAKDOWN DATA TRIANGULATION
- 18.5 MARKET SHARE ESTIMATION
- 18.6 STUDY ASSUMPTIONS
- 18.7 RESEARCH LIMITATIONS
- 18.7.1 METHODOLOGY-RELATED LIMITATIONS
- 18.8 RISK ASSESSMENT
19 APPENDIX
- 19.1 DISCUSSION GUIDE
- 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 19.3 CUSTOMIZATION OPTIONS
- 19.4 RELATED REPORTS
- 19.5 AUTHOR DETAILS